Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning Letter Blasts Mylan’s Lax API Impurity Controls

Cites Equipment Cleaning And Monitoring Of Recovered Solvents For Impurities

Executive Summary

Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.

You may also be interested in...



Mylan Hits Back At ‘Misleading’ FDA Warning Letter

Mylan has hit back at “misleading information” circulating in connection with a recent FDA warning letter – including some statements within the letter itself – as it highlighted its proactive efforts in investigating “all potential risks associated with inquiries related to nitrosamine impurities.”

Vega Life Sciences Warning Letter Shows Difficulty Of Applying Drug GMPs To API Solvent Recyclers

Recycling offers economic and environmental benefits, but risks introducing potentially carcinogenic impurities. Company barred from US market.

Mylan Warning Letter Exposes Challenges In Valsartan Supply Chain Chemistry

Nitrosamines taint Mylan’s valsartan API solvent recovery, whether outsourced or in-house; firm mulls US FDA's request for ‘material systems review.’

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel